Time interval distribution of hepatitis B vaccine immunization among infants in China from 2017 to 2021

Sihui Zhang; Xiaoling Tian; Li Wang; Ming Liu; Chao Wang; Tianshuo Zhao; Xianming Cai; Xiyu Zhang; Mingting Wang; Juan Du; Yaqiong Liu; Qingbin Lu; Jiang Wu; Ninghua Huang; Fuqiang Cui

doi:10.1080/21645515.2024.2395087

Human Vaccines & Immunotherapeutics (Dec 2024)

Time interval distribution of hepatitis B vaccine immunization among infants in China from 2017 to 2021

Sihui Zhang,
Xiaoling Tian,
Li Wang,
Ming Liu,
Chao Wang,
Tianshuo Zhao,
Xianming Cai,
Xiyu Zhang,
Mingting Wang,
Juan Du,
Yaqiong Liu,
Qingbin Lu,
Jiang Wu,
Ninghua Huang,
Fuqiang Cui

Affiliations

Sihui Zhang: Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, P. R. China
Xiaoling Tian: Institute for Immunization and Prevention, Inner Mongolia Center for Disease Control and Prevention, Hohhot City, People’s Republic of China
Li Wang: Institute for Immunization and Prevention, Suzhou Center for Disease Control and Prevention, Suzhou, China
Ming Liu: Department of Infectious Disease, Guizhou Provincial Center for Disease Control and Prevention, Guiyang, China
Chao Wang: Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China
Tianshuo Zhao: Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, P. R. China
Xianming Cai: Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, P. R. China
Xiyu Zhang: Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, P. R. China
Mingting Wang: Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, P. R. China
Juan Du: Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China
Yaqiong Liu: Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China
Qingbin Lu: Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China
Jiang Wu: Institute for Immunization and Prevention, Beijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, Beijing, China
Ninghua Huang: Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China
Fuqiang Cui: Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China

DOI: https://doi.org/10.1080/21645515.2024.2395087
Journal volume & issue: Vol. 20, no. 1

Abstract

Read online

Infant hepatitis B vaccine coverage in China is high, with over 95% of infants immunized; however, high vaccine coverage can often mask low timeliness. The vaccination interval between the second and third doses is not clearly defined by immunization guidelines in China. This retrospective cohort study assessed the time interval distribution of hepatitis B vaccination among a cohort of randomly selected live births from the Centers for Disease Control and Prevention across four provinces or municipalities in China between January 2017 and December 2021. Among the infants analyzed, 163,224 received the first dose of hepatitis B vaccine with 146,905 (90.0%) and 135,757 (83.2%) infants receiving the second and third doses, respectively. A total of 132,577 (90.2%) infants received the second dose between 28 and 61 days after the first dose. Of the 119,437 (88.0%) infants that completed the hepatitis B series between 61 and 214 days after the second dose 87,067 (64.1%) infants were vaccinated with the third dose between 151 and 180 days after the second dose. The time interval distribution varied across the four provinces or municipalities (p < .001). Of the 58,077 infants who completed the hepatitis B vaccine series, 36,377 (62.6%) infants used the same type of hepatitis B vaccine for all three doses. Overall, the timeliness of hepatitis B vaccination for infants was lower than expected, with regional disparities observed. This highlights the need for improved timeliness through the introduction of a defined timeframe for the last two doses of vaccine and training for obstetricians and related personnel.

Published in Human Vaccines & Immunotherapeutics

ISSN: 2164-5515 (Print); 2164-554X (Online)
Publisher: Taylor & Francis Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy; Medicine: Therapeutics. Pharmacology
Website: https://www.tandfonline.com/journals/khvi

About the journal

Abstract

Keywords